ArticlePloS one2016
Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Virulence factors released by extracellular vesicles fromFrontiers in cellular and infection microbiology · 2025Review
- Inbred Mouse Models inJournal of fungi (Basel, Switzerland) · 2024Review
- A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis.European journal of pharmacology · 2023Article
- Role of sphingolipids in the host-pathogen interaction.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2023Article
- T cell infiltration into the brain triggers pulmonary dysfunction in murine Cryptococcus-associated IRIS.Nature communications · 2023Article
- Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies.Expert review of anti-infective therapy · 2020Review
- Limited Role of Mincle in the Host Defense against Infection with Cryptococcus deneoformans.Infection and immunity · 2020Article
- Protective effect of fungal extracellular vesicles against murine candidiasis.Cellular microbiology · 2020Article
- Animal Models ofFrontiers in immunology · 2020Review
- Structural Differences Influence Biological Properties of Glucosylceramides from Clinical and Environmental Isolates ofJournal of fungi (Basel, Switzerland) · 2019Article
- Immunization Strategies for the Control of Histoplasmosis.Current tropical medicine reports · 2019Article
- Article
- A Call to Arms: Quest for a Cryptococcal Vaccine.Trends in microbiology · 2018Review
- Analysis of sphingolipids, sterols, and phospholipids in human pathogenicJournal of lipid research · 2017Article
- Nutritional Requirements and Their Importance for Virulence of Pathogenic Cryptococcus Species.Microorganisms · 2017Review
- The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017Review
- Fungal Glucosylceramide-Specific Camelid Single Domain Antibodies Are Characterized by Broad Spectrum Antifungal Activity.Frontiers in microbiology · 2017Article
- Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.Frontiers in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Cryptococcus neoformans is an opportunistic fungal pathogen and the causative agent of the disease cryptococcosis. Cryptococcosis is initiated as a pulmonary infection and in conditions of immune deficiency disseminates to the blood stream and central nervous system, resulting in life-threatening meningoencephalitis. A number of studies have focused on the development of a vaccine against Cryptococcus, primarily utilizing protein-conjugated components of the Cryptococcus polysaccharide capsule as antigen. However, there is currently no vaccine against Cryptococcus in the clinic. Previous studies have shown that the glycosphingolipid, glucosylceramide (GlcCer), is a virulence factor in C. neoformans and antibodies against this lipid inhibit fungal growth and cell division. In the present study, we have investigated the possibility of using GlcCer as a therapeutic agent against C. neoformans infections in mouse models of cryptococcosis. GlcCer purified from a non-pathogenic fungus, Candida utilis, was administered intraperitoneally, prior to infecting mice with a lethal dose of C. neoformans. GlcCer administration prevented the dissemination of C. neoformans from the lungs to the brain and led to 60% mouse survival. GlcCer administration did not cause hepatic injury and elicited an anti-GlcCer antibody response, which was observed independent of the route of administration and the strains of mouse. Taken together, our results suggest that fungal GlcCer can protect mice against lethal doses of C. neoformans infection and can provide a viable vaccination strategy against Cryptococcus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.